Terence W. Friedlander
About
Terence W. Friedlander is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Terence W. Friedlander has authored 112 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 51 papers in Surgery. Recurrent topics in Terence W. Friedlander's work include Bladder and Urothelial Cancer Treatments (50 papers), Prostate Cancer Treatment and Research (41 papers) and Cancer Immunotherapy and Biomarkers (40 papers). Terence W. Friedlander is often cited by papers focused on Bladder and Urothelial Cancer Treatments (50 papers), Prostate Cancer Treatment and Research (41 papers) and Cancer Immunotherapy and Biomarkers (40 papers). Terence W. Friedlander collaborates with scholars based in United States, Canada and France. Terence W. Friedlander's co-authors include Sandy Srinivas, Charles J. Ryan, Christopher Hoimes, Pamela L. Paris, Gayatri Premasekharan, Peter H. O’Donnell, Jingsong Zhang, Michael Ong, Srikala S. Sridhar and Joyce Antal and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Terence W. Friedlander
101 papers receiving 3.0k citations
Hit Papers
Peers
Terence W. Friedlander
Eishi Nagai Japan
An Na Seo South Korea
Kosei Hasegawa Japan
Ruth Perets Israel
Ashley Cimino‐Mathews United States
Florian Gebauer Germany
William K. Kelly United States
Sean P. Pitroda United States
Michiel S. van der Heijden Netherlands
Lillian Werner United States
Citations per year, relative to Terence W. Friedlander Terence W. Friedlander (= 1×)
peers
Eishi Nagai
Countries citing papers authored by Terence W. Friedlander
Since
Specialization
Citations
This map shows the geographic impact of Terence W. Friedlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence W. Friedlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence W. Friedlander more than expected).
Fields of papers citing papers by Terence W. Friedlander
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Terence W. Friedlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence W. Friedlander. The network helps show where Terence W. Friedlander may publish in the future.
Co-authorship network of co-authors of Terence W. Friedlander
This figure shows the co-authorship network connecting the top 25 collaborators of Terence W. Friedlander. A scholar is included among the top collaborators of Terence W. Friedlander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terence W. Friedlander. Terence W. Friedlander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.
2.
Loriot, Yohann, Arlene O. Siefker‐Radtke, Terence W. Friedlander, et al.. (2025). A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).. Journal of Clinical Oncology. 43(5_suppl).
3.
Loriot, Yohann, Arlene O. Siefker‐Radtke, Terence W. Friedlander, et al.. (2024). A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.. Journal of Clinical Oncology. 42(16_suppl). TPS4619–TPS4619.
4.
Kwon, Daniel H., Hala T. Borno, Rohit Bose, et al.. (2024). Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer Medicine. 13(22). e70433–e70433.
5.
Chou, Jonathan, et al.. (2023). Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series. Clinical Genitourinary Cancer. 22(2). 315–321.
6.
Oh, David Y., Anthony Wong, Katsuto Shinohara, et al.. (2023). 862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients. SHILAP Revista de lepidopterología. A961–A961.
7.
Wang, Elizabeth, Hala T. Borno, Samuel L. Washington, et al.. (2023). Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR Cancer. 9. e45432–e45432.
8.
Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2023). A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab. Future Oncology. 20(7). 351–360.
9.
Gupta, Shilpa, Omar Alhalabi, Aristotelis Bamias, et al.. (2023). 2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo). Annals of Oncology. 34. S1225–S1225.
10.
Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology. 41(1). 22–31.
11.
Chou, Jonathan, Martin Sjöström, Emily A. Egusa, et al.. (2022). TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. European Urology Oncology. 5(6). 714–718.
12.
Aggarwal, Rahul, Ivan de Kouchkovsky, Eric J. Small, et al.. (2022). 1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1173–S1173.
13.
Chu, Carissa, Martin Sjöström, Emily A. Egusa, et al.. (2021). Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clinical Cancer Research. 27(18). 5123–5130.
14.
Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524.
15.
Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, et al.. (2018). Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. Journal for ImmunoTherapy of Cancer. 6(1). 4–4.
16.
Wei, Xiao X., Serena S. Kwek, Jera Lewis, et al.. (2016). Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunology Research. 4(11). 948–958.
17.
Premasekharan, Gayatri, Elizabeth Gilbert, Ross A. Okimoto, et al.. (2016). An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters. 380(1). 144–152.
18.
Anantharaman, Archana & Terence W. Friedlander. (2015). Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. Urologic Oncology Seminars and Original Investigations. 34(8). 356–367.
19.
Kim, Won, Li Zhang, John H. Wilton, et al.. (2014). Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. Clinical Cancer Research. 20(24). 6269–6276.
20.
Friedlander, Terence W., Ritu Roy, Scott A. Tomlins, et al.. (2011). Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer. Cancer Research. 72(3). 616–625.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eishi Nagai Breakdown of academic impact, for papers by An Na Seo Breakdown of academic impact, for papers by Kosei Hasegawa Breakdown of academic impact, for papers by Ruth Perets Breakdown of academic impact, for papers by Ashley Cimino‐Mathews Breakdown of academic impact, for papers by Florian Gebauer Breakdown of academic impact, for papers by William K. Kelly Breakdown of academic impact, for papers by Sean P. Pitroda Breakdown of academic impact, for papers by Michiel S. van der Heijden Breakdown of academic impact, for papers by Lillian Werner